It is well-established that angiogenesis is implicated in CRC development and progression, and the therapeutic agents targeted pro-angiogenic biomarker vascular endothelial growth factor (VEGF) have been incorporated into standard CRC treatment (Mousa et al. 2015). Here, VEGFA is linked to colorectal carcinoma.